Hosted on MSN2h
FDA approves 'ketamine' nasal spray for depression — here's everything you need to knowA nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...
As major U.S. indexes like the Dow Jones, S&P 500, and Nasdaq Composite are on track for gains amid positive earnings reports and stable inflation data, investors continue to navigate a landscape ...
The following school districts have scheduled closures and delayed starts on Friday, Jan. 31 as a result of storm-related wintry conditions:Westchester CountyBedford Central School District, ...
For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to ...
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central ...
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback